Algert Global LLC Madrigal Pharmaceuticals, Inc. Transaction History

Algert Global LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$193.33 - $291.99 $245,335 - $370,535	1,269 New	1,269 $356,000
Q2 2023 Aug 14, 2023	SELL	$203.88 - $312.0 $500,729 - $766,272	-2,456 Reduced 24.89%	7,411 $1.71 Million
Q1 2023 May 12, 2023	BUY	$231.06 - $307.08 $281,200 - $373,716	1,217 Added 14.07%	9,867 $2.39 Million
Q4 2022 Feb 13, 2023	SELL	$58.39 - $296.54 $34,450 - $174,958	-590 Reduced 6.39%	8,650 $2.51 Million
Q3 2022 Nov 15, 2022	BUY	$60.57 - $79.51 $267,537 - $351,195	4,417 Added 91.58%	9,240 $601,000
Q1 2022 May 16, 2022	SELL	$55.89 - $101.89 $32,751 - $59,707	-586 Reduced 10.83%	4,823 $473,000
Q4 2021 Feb 14, 2022	BUY	$72.34 - $95.09 $391,287 - $514,341	5,409 New	5,409 $458,000

298

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.9B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.